Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use TALVEY safely and effectively. See full prescribing information for TALVEY. TALVEY™ (talquetamab-tgvs) injection, for subcutaneous use Initial U.S. Approval: 2023
Medication labelWhy this: Advisory · dailymed-prescription
TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- generic_name
- talquetamab
- product_names
- talquetamab
- ndc
- 57894-469, 57894-470, 57894-469-01, 57894-470-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en